Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Increases By 389.6%

Windtree Therapeutics, Inc. (NASDAQ:WINT) saw a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 151,300 shares, an increase of 389.6% from the November 15th total of 30,900 shares. Based on an average trading volume of 1,740,000 shares, the short-interest ratio is currently 0.1 days. Currently, 1.7% of the shares of the stock are short sold.

Windtree Therapeutics Stock Performance

Shares of NASDAQ:WINT traded down $0.01 during midday trading on Wednesday, reaching $0.36. The company’s stock had a trading volume of 317,878 shares, compared to its average volume of 803,454. The firm has a 50 day moving average price of $0.69 and a two-hundred day moving average price of $3.65. Windtree Therapeutics has a fifty-two week low of $0.35 and a fifty-two week high of $14.75. The firm has a market capitalization of $3.22 million, a price-to-earnings ratio of -0.02 and a beta of 0.54.

Analyst Ratings Changes

Separately, HC Wainwright restated a “neutral” rating and set a $7.00 price objective on shares of Windtree Therapeutics in a research report on Wednesday, December 4th.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.